R&D News | pharmaphorum

News

UK biotech sees "strong finish" to 2025 financing

2025 was a challenging year for the UK biotech sector, but it ended the year with signs of "renewed confidence," says the BIA industry body.

News

Boehringer signs €1bn+ deal for Simcere IBD candidate

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

News

Introducing the Sunday Times Tech 100: Life sciences part 2

In our second of three reports on the 2026 Sunday Times Tech 100, we focus on the first nine of 18 life sciences companies in the hardware category.

News

Thomas Appio, Bausch Health's chief executive

Bausch Health hit as Xifaxan successor flunks trials

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.

News

Pedestrian crossing green and red lights

MSD said to have pulled back from Revolution Meds deal

Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.

UK biotech sees "strong finish" to 2025 financing

Boehringer signs €1bn+ deal for Simcere IBD candidate

Roche claims midstage win for obesity injectable

Introducing the Sunday Times Tech 100: Life sciences part 2

Bausch Health hit as Xifaxan successor flunks trials

MSD said to have pulled back from Revolution Meds deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks